413 related articles for article (PubMed ID: 16861252)
41. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
42. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
43. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.
Nagashima H; Tezuka T; Tsuchida W; Maeda H; Kohroki J; Masuho Y
Mol Immunol; 2008 May; 45(10):2752-63. PubMed ID: 18353438
[TBL] [Abstract][Full Text] [Related]
44. Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells.
Ranft K; Thepen T; Fischer R; Barth S; Stöcker M
Cancer Lett; 2009 Sep; 282(2):187-94. PubMed ID: 19345477
[TBL] [Abstract][Full Text] [Related]
45. Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
J Gastroenterol Hepatol; 2006 Sep; 21(9):1439-47. PubMed ID: 16911690
[TBL] [Abstract][Full Text] [Related]
46. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
47. Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.
Kellner C; Bruenke J; Horner H; Schubert J; Schwenkert M; Mentz K; Barbin K; Stein C; Peipp M; Stockmeyer B; Fey GH
Cancer Lett; 2011 Apr; 303(2):128-39. PubMed ID: 21339041
[TBL] [Abstract][Full Text] [Related]
48. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
[TBL] [Abstract][Full Text] [Related]
49. A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge.
Stevenson GT; Pindar A; Slade CJ
Anticancer Drug Des; 1989 Mar; 3(4):219-30. PubMed ID: 2930624
[TBL] [Abstract][Full Text] [Related]
50. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
[TBL] [Abstract][Full Text] [Related]
51. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
52. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
Davies J; Jiang L; Pan LZ; LaBarre MJ; Anderson D; Reff M
Biotechnol Bioeng; 2001 Aug; 74(4):288-94. PubMed ID: 11410853
[TBL] [Abstract][Full Text] [Related]
53. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Ferrara C; Grau S; Jäger C; Sondermann P; Brünker P; Waldhauer I; Hennig M; Ruf A; Rufer AC; Stihle M; Umaña P; Benz J
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12669-74. PubMed ID: 21768335
[TBL] [Abstract][Full Text] [Related]
54. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
55. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
Derer S; Kellner C; Berger S; Valerius T; Peipp M
Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
[TBL] [Abstract][Full Text] [Related]
56. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity.
Shinkawa T; Nakamura K; Yamane N; Shoji-Hosaka E; Kanda Y; Sakurada M; Uchida K; Anazawa H; Satoh M; Yamasaki M; Hanai N; Shitara K
J Biol Chem; 2003 Jan; 278(5):3466-73. PubMed ID: 12427744
[TBL] [Abstract][Full Text] [Related]
57. Novel anti-Tn single-chain Fv-Fc fusion proteins derived from immunized phage library and antibody Fc domain.
Kubota T; Matsushita T; Niwa R; Kumagai I; Nakamura K
Anticancer Res; 2010 Sep; 30(9):3397-405. PubMed ID: 20944114
[TBL] [Abstract][Full Text] [Related]
58. In vitro and in vivo properties of a dimeric bispecific single-chain antibody IgG-fusion protein for depletion of CCR2+ target cells in mice.
Schneider MA; Brühl H; Wechselberger A; Cihak J; Stangassinger M; Schlöndorff D; Mack M
Eur J Immunol; 2005 Mar; 35(3):987-95. PubMed ID: 15719369
[TBL] [Abstract][Full Text] [Related]
59. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells.
Zeidler R; Mysliwietz J; Csánady M; Walz A; Ziegler I; Schmitt B; Wollenberg B; Lindhofer H
Br J Cancer; 2000 Jul; 83(2):261-6. PubMed ID: 10901380
[TBL] [Abstract][Full Text] [Related]
60. Increased in vivo effector function of human IgG4 isotype antibodies through afucosylation.
Gong Q; Hazen M; Marshall B; Crowell SR; Ou Q; Wong AW; Phung W; Vernes JM; Meng YG; Tejada M; Andersen D; Kelley RF
MAbs; 2016; 8(6):1098-106. PubMed ID: 27216702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
